ArkVax
PrivateLast Round
Seed
Dec 5, 2022
Total Funding Raised
$13,000
Company Overview
ArkVax is a biotechnology company that develops recombinant glycoconjugate vaccines for animals through glycoengineering.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ArkVax Comparables
Compare ArkVax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Malcisbo AG | 85% | |
| Scaffold Biotech | 77% | |
| The Vaccine Group | 77% | |
ArkVax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Dec 5, 2022 | ||||
| Accelerator | Sep 21, 2020 |
ArkVax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Planet Capital Regional | Seed |
| Start Codon | Seed |
| Accelerate@Babraham | Accelerator |
| UK Innovation & Science Seed Fund | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 21, 2020
$13K raised from Accelerate@Babraham.
ArkVax Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ArkVax's valuation, stock price, and market status.